After three years and lots of back-and-forth, the FDA finally greenlit the Multidisciplinary Association for Psychedelic Studies’ (MAPS) Phase 2 study of smoked cannabis in veterans for the treatment of PTSD (MJP2). This study will test the safety and efficacy of inhaled cannabis (high THC) versus a placebo to manage PTSD symptoms and pain in about 320 veterans across Michigan and three other states. The study is backed by a $12.9 million grant from the Michigan Veteran Marijuana Research Grant Program, funded by state cannabis tax revenue.  Read the article here.